Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

Preparing to launch a new asset and in need of demand assessment research? Download our pre-launch checklist

Preparing to launch a new asset and in need of demand assessment research? Download our pre-launch checklist

An accurate forecast of customer appeal and likely future behaviour is critical to launch. We work with you to answer key questions when designing an effective market research study. Our research will give you the inputs you need for an accurate forecast.

read more »

China: How to strategise and win in the world's fastest changing healthcare market

China: How to strategise and win in the world's fastest changing healthcare market

In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.

With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.

read more »

  • Posted by Rachel Howard
  • October 23, 2019
  • Articles

Market access in Brazil: All eyes on Spinraza

Market access in Brazil: All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

read more »

How we helped our client identify where to play and how to win for their hospital product in India

How we helped our client identify where to play and how to win for their hospital product in India

Our client has a hospital care portfolio which is marketed globally. Despite a low per capita use of the product in India, the annual growth rate of usage is among the highest in the world. It was therefore critical for our client to understand which channels they should focus on (where to play) and what points of differentiation would enable them to gain market share in those chosen channels (how to win).
 

read more »

  • Posted by Pei Li Teh & Colin Tan
  • October 22, 2019
  • Events

Real world evidence research breakfast seminar

Real world evidence research breakfast seminar

We were delighted to attend and present a paper at the Tech Observer event in Singapore earlier this month

APAC Director Pei Li Teh, and Research Manager, Colin Tan, attended the event. Pei Li presented the paper ‘Inhale, exhale: How using real world data helped asthma patients breathe easier across Asia’. In her paper she demonstrated how published real world data research provided pharma companies with an in-depth understanding of asthma patients’ across Asia. The data provided the healthcare community with a tool to supply tailored communications supporting different patient types, instead of a ‘one size fits all’ approach.

read more »